LYON – September 3rd, 2024.
Under this unique partnership, Pfizer will gain access to Edelris’ unrivaled technologies in high-throughput synthesis and AS-MS screening for hit identification and optimization against several of Pfizer’s biological targets of interest.
With this agreement, Edelris will activate its expertise in high-value and bio-relevant library design and production, its proprietary, diverse, and lead-like 2Mio compound collection coupled with mass spectrometry-based screening technologies, and its creative and dedicated teams of expert research scientists.
In the last 20 years, Edelris has produced, on behalf of Pharma, Biotech, and University clients, over 12Mio novel compounds for screening and medicinal chemistry (HTS collections, Fragments collections, AS-MS and DEL collections, Covalent compound collections). We have discovered patent-free ligands for numerous difficult-to-drug targets (GPCR, E3-ligases, transcription factors, kinase modulators, metabolic and epigenetic enzymes…) and have worked with Targeted Protein Degraders since 2018.
More news
About Edelris
Expanding the boundaries for your small molecule drug discovery!
Edelris is a leading Drug Discovery CRO, providing Compound Libraries, Organic & Medicinal Chemistry, High Throughput Screening, and Analytical expert services to the Pharmaceutical, Cosmetic, Crop Protection, and Biotech sectors.
Cross-fertilizing our combined experiences, knowledge, and techniques, together we break through to successful solutions for you.